Contents of this article
The nervous system uses electrical impulses to transmit information rapidly, but much of its fine-tuned control depends on peptides. These small chains of amino acids act as neuropeptides, functioning as neurotransmitters, neuromodulators, and hormones that shape emotion, cognition, pain perception, stress responses, and circadian rhythms. From classical hypothalamic peptides that regulate appetite to peptide-targeted therapies for migraine, peptide signaling represents one of the most versatile modes of biological communication. Neuropeptides are evolutionarily conserved, highlighting their fundamental role in survival behaviors across species. Their ability to act locally at synapses and broadly across brain regions makes them essential regulators of both immediate responses and long-term physiological states.
Neuropeptides: The chemical language of the nervous system
Neuropeptides are short amino acid chains synthesized in neuronal cell bodies, packaged into dense-core vesicles, and transported to axon terminals. Unlike small-molecule neurotransmitters such as glutamate or dopamine, neuropeptides often act over longer timescales and diffuse to influence circuits rather than driving rapid excitatory or inhibitory signals. They bind primarily to G protein-coupled receptors (GPCRs), a receptor class that underpins much of peptide signaling. Because GPCRs are major drug targets, neuropeptides serve as a critical link between fundamental neuroscience and therapeutic innovation.
Co-transmission
Many neurons release neuropeptides alongside classical neurotransmitters, enabling dual modes of signaling. For example, a neuron may release glutamate for fast synaptic transmission and Substance P for prolonged modulation of pain pathways. Peptide release usually requires higher-frequency or burst firing compared to small-molecule transmitters, ensuring that neuropeptides are recruited under conditions of heightened neuronal activity.
Peptides in the central nervous system
Hypothalamic neuropeptides
The hypothalamus is a hub of neuropeptide production, regulating hunger, thirst, stress, and circadian rhythms:
- Orexin (hypocretin) controls arousal and wakefulness, with deficiency linked to narcolepsy.
- Neuropeptide Y (NPY) and Agouti-related peptide (AgRP) promote feeding, while POMC-derived peptides suppress appetite.
- Corticotropin-releasing hormone (CRH) coordinates stress responses via the HPA axis.
Pain and analgesia
The endogenous opioid system (endorphins, enkephalins, dynorphins) binds opioid receptors to reduce pain perception. This natural analgesic network is the basis for opioid drug effects and a target for safer next-generation pain therapies.
Mood, reward, and social behavior
- Oxytocin and vasopressin regulate bonding, trust, and social recognition, with active research into their role in autism spectrum disorders and social anxiety. Results remain mixed, requiring cautious interpretation.
- Substance P and NPY influence mood and anxiety states, with altered levels observed in depression and PTSD.
Peptides in the peripheral nervous system
In the peripheral nervous system (PNS), neuropeptides are key mediators of pain and inflammation:
- Substance P and Calcitonin gene-related peptide (CGRP) contribute to pain transmission and neurogenic inflammation.
- Therapies targeting CGRP signaling have become highly effective in migraine prevention and treatment.
Therapeutic Peptides in neurology
Migraine
CGRP-targeted therapeutics including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule antagonists (gepants) have significantly advanced migraine therapy.
- Zavegepant nasal spray provides rapid migraine relief and a favorable safety profile.
- Atogepant has demonstrated efficacy and tolerability in preventive treatment.
- A systematic review confirms the safety and efficacy of anti-CGRP therapies in chronic migraine populations.
Neurodegenerative disorders
Research is exploring peptides and peptidomimetics that:
- modulate amyloid-β aggregation in Alzheimer’s disease,
- interfere with α-synuclein pathology in Parkinson’s disease, and
- mimic neurotrophic peptides to support neuronal survival.
These approaches are promising but remain largely in preclinical or early clinical stages.
Psychiatric disorders
- Oxytocin analogs are being tested for autism and social anxiety, but clinical results are mixed.
- NPY-based interventions are under investigation for modulating stress and resilience.
Advances in Peptide delivery for the nervous system
Delivering peptides to the brain is challenging due to the blood-brain barrier (BBB) and rapid enzymatic degradation. Strategies include:
- Intranasal administration, which can bypass the BBB (e.g., oxytocin delivery).
- Lipidation and nanoparticle formulations to improve stability and transport.
- Peptidomimetics, small molecules that mimic peptide function but can be orally available.
Safety, access, and perspectives
Neuropeptide therapies offer receptor selectivity and the potential for favorable safety, but major challenges include:
- short half-life,
- limited BBB penetration,
- production cost,
- possible immunogenicity, and
- receptor desensitization.
The future of neuroscience likely involves multi-target peptide drugs, personalized neuropeptide modulation guided by genetics, and peptidomimetic strategies that combine the specificity of peptides with the practicality of small molecules.
Peptides add a powerful chemical layer to the brain’s electrical language, providing both precision and flexibility in how neural circuits operate. By shaping processes as diverse as stress resilience, social bonding, feeding, and pain control, they illustrate the nervous system’s reliance on chemical diversity for adaptive behavior. With advances in peptide-based therapies, the study of neuropeptides not only deepens our understanding of brain function but also offers new pathways for treating neurological and psychiatric disorders.
Research sources:
Neuropeptides and small-molecule amine transmitters: cooperative signaling in the nervous system
Lee E. Eiden, Vito S. Hernández, Sunny Z. Jiang and Limei Zhang. Published in Springer Nature Cellular and Molecular Life Sciences 2022 | DOI: 10.1007/s00018-022-04451-7
Mapping and decoding neuropeptide signaling networks in nervous system function
Isabel Beets and Jan Watteyne. Published in ScienceDirect Current Opinion in Neurobiology 2025 | DOI: 10.1016/j.conb.2025.103027
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniel Hoyer, Laura H. Jacobson, Kevin D. G. Pfleger and Elizabeth K. M. Johnstone. Published in Frontiers in Cellular Neuroscience 2022 | DOI: 10.3389/fncel.2022.812359
Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases
Xin Yi Yeo, Grace Cunliffe, Roger C. Ho, Su Seong Lee and Sangyong Jung. Published in MDPI Biomedicines 2022 | DOI: 10.3390/biomedicines10020343
Endogenous opioid systems alterations in pain and opioid use disorder
Jessica A. Higginbotham, Tamara Markovic, Nicolas Massaly and Jose A. Morón. Published in Frontiers in Systems Neuroscience 2022 | DOI: 10.3389/fnsys.2022.1014768
Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities
Nicole Rigney, Geert J de Vries, Aras Petrulis and Larry J Young. Published in Oxford Academix Endocrinology 2022 | DOI: 10.1210/endocr/bqac111
Neuropeptide Y: A stressful review
Florian Reichmann and Peter Holzer. Published in ScienceDirect Neuropeptides 2016 | DOI: 10.1016/j.npep.2015.09.008
Protective Role and Functional Engineering of Neuropeptides in Depression and Anxiety: An Overview
Nathalie Okdeh, Georges Mahfouz, Julien Harb, Jean-Marc Sabatier, Rabih Roufayel, Eddie Gazo Hanna, Hervé Kovacic and Ziad Fajloun. Published in MDPI Bioengineering 2023 | DOI: 10.3390/bioengineering10020258
Zixiang Zhu, Yanbing Tang, Longyuan Li, Hanyu Ni, Meirong Liu, Zhouqing Chen and Zhong Wang. Published in The Journal of Headache and Pain 2025 | DOI: 10.1186/s10194-025-01984-7
Min Hou, Xiaofeng Luo, Shuangshuang He, Xue Yang, Qing Zhang, Meihua Jin, Pan Zhang, Yang Li, Xiaoting Bi, Juan Li, Caiyi Cheng, Qiang Xue, Haiyan Xing and Yao Liu. Published in The Journal of Headache and Pain 2024 | DOI: 10.1186/s10194-024-01822-2
Feedforward inhibition of stress by brainstem neuropeptide Y neurons
Yan Zhang, Jiayi Shen, Famin Xie, Zhiwei Liu, Fangfang Yin, Mingxiu Cheng, Liang Wang, Meiting Cai, Herbert Herzog, Ping Wu, Zhi Zhang, Cheng Zhan and Tiemin Liu. Published in Nature Communications 2024 | DOI: 10.1038/s41467-024-51956-9
Intranasal Administration for Pain: Oxytocin and Other Polypeptides